



## REVISIÓN DE LA LITERATURA. ENFERMEDADES INFECCIOSAS (VIH)

**Dr. Jose R Arribas**

Unidad de Enfermedades Infecciosas. Hospital Universitario La Paz, Madrid

### *TAR DUAL*

1. Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial. *Clin Infect Dis* 2022;ciac130. <https://doi.org/10.1093/cid/ciac130>

### *PREP DE ACCION PROLONGADA*

2. Delany-Moretlwe S, Hughes JP, Bock P, et al. **Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.** *Lancet* 2022;S0140-6736(22)00538-4.
3. Landovitz RJ, Donnell D, Clement ME, et al. **Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.** *N Engl J Med* 2021;385(7):595–608.

### *TAR DE ACCION PROLONGADA*

4. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. *Lancet* 2021;396(10267):1994–2005.

### *TAR DE RESCATE*

5. Paton NI, Musaaazi J, Kityo C, et al. **Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.** *N Engl J Med* 2021;385(4):330–41.

### *CURACIÓN*

6. Turk G, Seiger K, Lian X, et al. **A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation.** *Ann Intern Med* 2022;175(1):95–100.



*INFECCIONES OPORTUNISTAS*

7. Jarvis JN, Lawrence DS, Meya DB, et al. **Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.** *N Engl J Med* 2022;386(12):1109–20.

*COVID-19*

8. Iketani S, Liu L, Guo Y, et al. **Antibody evasion properties of SARS-CoV-2 Omicron sublineages.** *Nature* 2022;604(7906):553–6.
9. Hammond J, Leister-Tebbe H, Gardner A, et al. **Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.** *N Engl J Med* 2022;386(15):1397–408.
10. Gottlieb RL, Vaca CE, Paredes R, et al. **Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.** *N Engl J Med* 2022;386(4):305–15.
11. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. **Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.** *N Engl J Med* 2022;386(6):509–20.